US 9,809,623 B2
α4β7 peptide monomer and dimer antagonists
Ashok Bhandari, Pleasanton, CA (US); Dinesh V. Patel, Fremont, CA (US); Genet Zemede, San Jose, CA (US); Larry C. Mattheakis, Cupertino, CA (US); and David Liu, Milpitas, CA (US)
Assigned to Protagonist Therapeutics, Inc., Newark, CA (US)
Filed by Protagonist Therapeutics, Inc., Milpitas, CA (US)
Filed on Oct. 1, 2015, as Appl. No. 14/872,975.
Claims priority of provisional application 62/192,934, filed on Jul. 15, 2015.
Claims priority of provisional application 62/149,257, filed on Apr. 17, 2015.
Claims priority of provisional application 62/058,506, filed on Oct. 1, 2014.
Claims priority of provisional application 62/058,510, filed on Oct. 1, 2014.
Prior Publication US 2016/0152664 A1, Jun. 2, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/725 (2006.01); A61K 38/00 (2006.01)
CPC C07K 7/08 (2013.01) [C07K 7/06 (2013.01); C07K 14/7051 (2013.01); A61K 38/00 (2013.01)] 14 Claims
 
1. A method for treating an inflammatory bowel disease in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide dimer compound comprising two monomer subunits, wherein each monomer subunit comprises the amino acid sequence:
Pen-(N-Me-Arg)-Ser-Asp-Thr-Leu-Pen-Phe(4-tBu)-(β-homo-Glu)-(D-Lys),
or a pharmaceutically acceptable salt thereof,and wherein the two monomer subunits are linked by a linker moiety.